A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair (ATLAS)

C. R. Bard

Status

Completed

Conditions

Incisional Hernia

Hernia, Ventral

Treatments

Device: Phasix™ ST

Study type

Interventional

Funder types

Industry

Identifiers

NCT02712398

DVL-HE-017

Details and patient eligibility

About

The objective of this study is to collect additional data on safety, performance and effectiveness of Phasix™ ST in subjects receiving laparoscopic ventral or incisional hernia repair at high risk for surgical site occurrence (SSO).

Full description

Subjects at high risk are defined as having 1 or more of the following co-morbid conditions: body mass index (BMI) between 30-40 kg/m2, inclusive, active smokers, chronic obstructive pulmonary disease (COPD), diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, low pre-operative serum albumin, advanced age, or renal insufficiency.

Enrollment

120 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject must be 18 years of age or older
Subject must be willing to give written informed consent
Subject must be diagnosed with ventral or abdominal incisional hernia
Subject must be willing to undergo laparoscopic hernia repair using intraabdominal placement (with or without Component Separation Technique (CST))
Surgeon must be able to fully close the hernia defect. Defect closure is defined as complete reapproximation of fascial edges, leaving no gap. Since the safety and effectiveness of Phasix™ ST Mesh in bridging repairs has not been evaluated or established, the defect should be closed prior to mesh use.
Subject is expected to meet the criteria for a Class I wound
Subjects must have 1 or more of the following pre-study conditions:
1. Body Mass Index (BMI) between 30-40 kg/m2, inclusive
2. Active smoker (including if attempts to quit smoking within two weeks of surgery have failed and the patient is still an active smoker at the time of surgery)
3. COPD presence on patient self-report
4. Diabetes mellitus (if yes, diagnosis to be confirmed via medical records or laboratory results according to 2014 Joslin Clinical Guideline for Adults with Diabetes)(Appendix 5)
5. Immunosuppression
6. Coronary Artery Disease
7. Chronic corticosteroid use: greater than 6 months systemic use
8. Serum albumin less than 3.4 g/dL
9. Advanced age: 75 years or older
10. Renal insufficiency, defined as serum creatinine concentration ≥2.5 mg/dL

Exclusion criteria

Subject has had 4 or more previous hernia repairs (of the index hernia)
Subject's hernia is > 350 cm2
Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible
Subject has intact permanent mesh adjacent to the current hernia to be repaired
Preperitoneal placement of mesh
The subject is known to have a collagen disorder
The subject has peritonitis
The subject is on or suspected to be placed on chemotherapy medications during any part of the study
The subject's Body Mass Index (BMI) is > 40 kg/m2
The subject has cirrhosis of the liver and/or ascites
Subject is American Society of Anesthesiology Class 4 or 5
Subject has a life expectancy of less than 2 years at the time of enrollment
Subject has any condition that, in the opinion of the Investigator, would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
Subject has a surgical wound classified as Class II (Clean-Contaminated), Class III (Contaminated) or Class IV (Dirty-Contaminated)
Subject has an active or latent systemic infection
Patient has a contraindication to placement of mesh
Subject requires surgical bridge repair as the sole repair
Subject is pregnant or has plans to become pregnant during the study period
Subject has enrolled in another interventional clinical study within the last 30 days
Subject is part of the site personnel directly involved with this study
Subject has a known allergy to the test device or component materials (patients with known allergies to tetracycline hydrochloride or kanamycin sulfate should be avoided).